925-56-4

Basic information

• Product Name: methyl (2E)-3-cyanoprop-2-enoate
• Synonyms: (E)-Methyl 3-cyano-2-propenoate
• CAS NO: 925-56-4
• Molecular Formula: C₅H₅NO₂
• Molecular Weight: 111.0987
• Mol File: 925-56-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 190.1°C at 760 mmHg
• Flash Point: 76.4°C
• Density: 1.094g/cm³
• Vapor Pressure: 0.551mmHg at 25°C
• Refractive Index: 1.443
• CAS DataBase Reference: methyl (2E)-3-cyanoprop-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2E)-3-cyanoprop-2-enoate(925-56-4)
• EPA Substance Registry System: methyl (2E)-3-cyanoprop-2-enoate(925-56-4)

Safety Data

• Hazardous Substances Data: 925-56-4(Hazardous Substances Data)

Upstream product

• 74-90-8 hydrogen cyanide 
• 151-50-8 potassium cyanide 
• 922-67-8 propynoic acid methyl ester 
• 79-22-1 methyl chloroformate 
• 2345-56-4 Malonamic acid 
• 80-63-7 methyl 2-chloroacrylate 
• 143-33-9 sodium cyanide 
• 6971-10-4 (E)-4-amino-4-oxo-2-butenoic acid methyl ester 
• 17081-97-9 methyl (E)-4-chloro-4-oxo-2-butenoate 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 2756-87-8 methyl hydrogen fumarate 
• 114980-39-1 3,3-dimethoxydiazirine 
• 920-37-6 2-Chloroacrylonitrile 
• 107-13-1 acrylonitrile 

Downstream Products

• 97311-73-4 3-Cyan-2-cyclohexylpropansaeure-methylester 
• 97311-72-3 3-Cyan-3-cyclohexylpropansaeure-methylester 
• 127183-76-0 (2α,3α,4α,5α)-(+/-)-3-Methyl 2-phenylmethyl 4-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,3-pyrrolidinedicarboxylate 
• 127183-75-9 (2α,3α,4α,5β)-(+/-)-4-Methyl 2-phenylmethyl 3-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,4-pyrrolidinedicarboxylate 
• 127183-75-9 (2α,3α,4β,5β)-(+/-)-4-Methyl 2-phenylmethyl 3-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,4-pyrrolidinedicarboxylate 
• 196808-10-3 3-[(3aS,4S,6aS)-6a-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-pyrrolidine-2,5-dione 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Pyrazolopyrimidine derivative, preparation method, pharmaceutical composition and application

The invention discloses a pyrazolopyrimidine derivative, a preparation method, a pharmaceutical composition and application. The invention provides the pyrazolopyrimidine derivative as shown in a formula I and stereoisomer or solvate or pharmaceutically acceptable salts or active metabolite or prodrug thereof. The pyrazolopyrimidine derivative as shown in the formula I has good inhibitory activity on Bruton's tyrosine kinase (Btk) and particularly has good in vitro and in vivo inhibitory activity on growth of tumor cells, and a good marketization prospect is achieved. Please see the formula I in the description.

Highly active phosphine-free carbene ruthenium catalyst for cross-metathesis of acrylonitrile with functionalized olefins

The carbene ruthenium complex [1,3-bis(2,6-dimethylphenyl)-4,5- dihydroimidazol-2-ylidene](C5H5N)2(Cl) 2RuCHPh (8) was prepared by the reaction of [1,3-bis (2,6-dimethylphenyl)-4,5-dihydroimidazol-2-ylidene](PPh3)(Cl) 2RuCHPh (7) with pyridine and used as a highly effective catalyst for the cross-metathesis of acrylonitrile with various functionalized olefins.